SCHEMBL1878372

SCHEMBL1878372

Cc1ccc(C(=O)NN)cc1Br

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGD P15428 5/20 0.62
ALDH1A1 P00352 3/20 0.60
SMN1; SMN2 Q16637 3/20 0.59
RAB9A P51151 2/20 0.59
NPC1 O15118 1/20 0.59
MTOR P42345 6/20 0.56
OGG1 O15527 1/20 0.55
NPSR1 Q6W5P4 1/20 0.54
TDP1 Q9NUW8 2/20 0.52
KDM4E B2RXH2 1/20 0.52
LMNA P02545 1/20 0.52
GAA P10253 1/20 0.52
L3MBTL1 Q9Y468 1/20 0.52
MAPK14 Q16539 1/20 0.51
POLB P06746 1/20 0.51
MAPT P10636 1/20 0.51
HTT P42858 1/20 0.51
DUSP3 P51452 1/20 0.51
PTPN5 P54829 1/20 0.51
PTPN11 Q06124 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1459893 0.85 OGG1 (0.55) HPGDALDH1A1SMN1; SMN2RAB9ANPC1
SCHEMBL18329647 0.83 SMN1; SMN2 (0.61) HPGDALDH1A1SMN1; SMN2RAB9ANPC1
SCHEMBL5487653 0.82 NR1H4 (0.56) ALDH1A1SMN1; SMN2RAB9ANPC1OGG1
SCHEMBL13753864 0.82 HPGD (0.68) HPGDALDH1A1SMN1; SMN2RAB9ANPC1
SCHEMBL6659819 0.80 HPGD (0.59) HPGDALDH1A1SMN1; SMN2RAB9ANPC1
SCHEMBL2648578 0.79 OGG1 (0.57) ALDH1A1SMN1; SMN2RAB9ANPC1OGG1
SCHEMBL21638086 0.79 OGG1 (0.57) HPGDALDH1A1SMN1; SMN2RAB9ANPC1
SCHEMBL30015840 0.79 OGG1 (0.57) HPGDALDH1A1SMN1; SMN2RAB9ANPC1
SCHEMBL1628213 0.79 ALDH1A1 (0.57) ALDH1A1OGG1TDP1KDM4ELMNA
SCHEMBL4809042 0.79 MAPT (0.66) ALDH1A1SMN1; SMN2OGG1TDP1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 73 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10292981-B2 Oxazoline and isoxazoline derivatives as CRAC modulators LUPIN LIMITED (IN) 2019-05-21 US disclosed
US-10000458-B2 Production method of 1, 2, 4-triazole compound SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2018-06-19 US disclosed
US-20170304299-A1 OXAZOLINE AND ISOXAZOLINE DERIVATIVES AS CRAC MODULATORS LUPIN LTD (IN) 2017-10-26 US disclosed
US-20170304299-A1 OXAZOLINE AND ISOXAZOLINE DERIVATIVES AS CRAC MODULATORS LUPIN LTD (IN) 2017-10-26 US disclosed
US-20170304299-A1 OXAZOLINE AND ISOXAZOLINE DERIVATIVES AS CRAC MODULATORS LUPIN LTD (IN) 2017-10-26 US disclosed
US-20170283383-A1 PRODUCTION METHOD OF 1, 2, 4-TRIAZOLE COMPOUND SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2017-10-05 US disclosed
US-20170283383-A1 PRODUCTION METHOD OF 1, 2, 4-TRIAZOLE COMPOUND SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2017-10-05 US disclosed
US-9737534-B2 Oxazoline and isoxazoline derivatives as CRAC modulators LUPIN LIMITED (IN) 2017-08-22 US disclosed
US-9737534-B2 Oxazoline and isoxazoline derivatives as CRAC modulators LUPIN LIMITED (IN) 2017-08-22 US disclosed
US-9737534-B2 Oxazoline and isoxazoline derivatives as CRAC modulators LUPIN LIMITED (IN) 2017-08-22 US disclosed
EP-1435950-A1 2'-METHYL-5'-(1,3,4-OXADIAZOL-2-YL)-1,1'-BIPHENYL-4-CARBOXAMIDE DERIVATIVES AND THEIR USE AS P38 KINASE INHIBITORS GLAXO GROUP LIMITED (GB) 2004-07-14 EP disclosed
EP-1435949-A1 2' -METHYL-5-(1,3,4-OXADIAZOL-2-YL)-1,1'-BIPHENYL-4-CARBOXAMIDE DERIVATIVES AND THEIR USE AS P38 KINASE INHIBITORS GLAXO GROUP LIMITED (GB) 2004-07-14 EP disclosed
WO-2003032986-A1 2' -METHYL-5-(1,3,4-OXADIAZOL-2-YL)-1,1'-BIPHENYL-4-CARBOXAMIDE DERIVATIVES AND THEIR USE AS P38 KINASE INHIBITORS GLAXO GROUP LIMITED (GB) 2003-04-24 WO disclosed
WO-2003033482-A1 OXADIAZOLYL-BIPHENYLCARBOXAMIDES AND THEIR USE AS P38 KINASE INHIBITORS GLAXO GROUP LIMITED (GB) 2003-04-24 WO disclosed
WO-2003032987-A1 2'-METHYL-5'-(1,3,4-OXADIAZOL-2-YL)-1,1'-BIPHENYL-4-CARBOXAMIDE DERIVATIVES AND THEIR USE AS P38 KINASE INHIBITORS GLAXO GROUP LIMITED (GB) 2003-04-24 WO disclosed
EP-0368237-B1 Polymer bound flame retardants ATOCHEM NORTH AMERICA (US) 1995-04-12 EP disclosed
US-5220015-A Having hydrazide group to chemically bond to anhydride-containing polymers ELF ATOCHEM NORTH AMERICA, INC. (US) 1993-06-15 US disclosed
US-5140070-A Halogenated aromatic compounds having acylamino functional groups bonded to imide containing polymer ELF ATOCHEM NORTH AMERICA, INC (US) 1992-08-18 US disclosed
US-5037894-A Maleic anhydride polymer reacted with halogenated hydrazide compound or derivative ATOCHEM NORTH AMERICA, INC. (US) 1991-08-06 US disclosed
EP-0368237-A2 Polymer bound flame retardants ELF ATOCHEM NORTH AMERICA, INC. (US) 1990-05-16 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10000458-B2 Production method of 1, 2, 4-triazole compound HRH4, HRH3, HRH2 HPGD 1759/4885ALDH1A1 362/4885SMN1; SMN2 4851/4885
US-10292981-B2 Oxazoline and isoxazoline derivatives as CRAC modulators RYR2, RYR1, ADRA2C HPGD 1592/4885ALDH1A1 655/4885SMN1; SMN2 900/4885
US-20170304299-A1 OXAZOLINE AND ISOXAZOLINE DERIVATIVES AS CRAC MODULATORS RYR2, ADRA2C, RYR1 HPGD 1620/4885ALDH1A1 607/4885SMN1; SMN2 856/4885
US-20170283383-A1 PRODUCTION METHOD OF 1, 2, 4-TRIAZOLE COMPOUND HRH4, HRH3, HRH2 HPGD 1759/4885ALDH1A1 362/4885SMN1; SMN2 4851/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.